Defunct Company
Total Trials
14
As Lead Sponsor
As Collaborator
0
Total Enrollment
922
NCT01863485
Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China
Phase: Phase 1
Role: Lead Sponsor
Start: May 31, 2013
Completion: May 31, 2016
NCT02452385
Phase 1 Study of CM082 in Patients With wAMD
Start: Mar 31, 2015
Completion: Jun 30, 2020
NCT02577458
Study of the Combination of CM082 With Everolimus in Patients With mRCC
Start: Sep 30, 2015
Completion: Jun 30, 2018
NCT03095040
CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma
Phase: Phase 3
Start: Dec 16, 2016
Completion: Dec 31, 2021
NCT03286244
Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer
Start: Mar 15, 2018
Completion: Aug 31, 2020
NCT03602547
Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.
Phase: Phase 2
Start: Jul 31, 2018
NCT03710863
Safety and Tolerability of Oral CM082 in Patients With wAMD
Start: Nov 22, 2018
Completion: Jan 1, 2022
NCT03792958
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors
Start: Feb 26, 2019
Completion: Jun 30, 2023
NCT03848611
CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).
Start: Apr 2, 2019
Completion: Sep 30, 2021
NCT03904719
CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)
Start: Sep 18, 2019
NCT04222842
CM082 in Patients With Myopic Choroidal Neovascularization (CNV)
Start: Dec 18, 2019
Completion: Dec 30, 2021
NCT04126668
A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers
Start: Dec 19, 2019
Completion: Jan 16, 2020
NCT04328506
Bioequivalency Study of CM082 Tablet in Healthy Volunteers
Start: Jun 1, 2020
Completion: Jul 27, 2020
NCT04434326
The Absorption, Metabolism and Excretion of [14C]CM082 in Human
Start: Jul 5, 2021
Completion: Oct 22, 2021